Biofidelity, a Cambridge-based genomic technology company at the commercial stage, has announced a significant funding boost of $24M (approximately €22M), bringing its total funding to $60M (approximately €55.3M). This round of financing was supported by current investors, including Agilent Technologies, Octopus Ventures, BlueYard Capital, and Longwall Ventures.